AstraZeneca Achieves 43% UPCR Reduction with Ultomiris in Phase III IgA Nephropathy Trial

AstraZeneca's Ultomiris (ravulizumab) has delivered a statistically significant interim readout in IgA nephropathy, a result that now positions the company's biologics manufacturing network for a potential new indication filing with both FDA and EMA. At 34 weeks, the complement C5 inhibitor achieved a 43.4% placebo-adjusted reduction in 24-hour urine protein creatinine ratio (UPCR), meeting the study's key interim endpoint.

For QA directors and regulatory leads tracking the complement inhibitor space, the UPCR endpoint carries direct weight: it is an accepted surrogate marker in nephrology trials and aligns with agency expectations for accelerated or standard approval pathways under existing guidance frameworks. A successful Phase III interim of this magnitude typically triggers pre-submission engagement with regulators, meaning supplemental Biologics License Application (sBLA) and Type II variation timelines could be initiated within the near term.

On the manufacturing side, Ultomiris is already approved for paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), so AstraZeneca's biologics fill-finish and supply chain infrastructure is established. A new IgA nephropathy indication, however, introduces a distinct patient population with potentially different dosing schedules and volume projections, requiring updated process validation packages and batch record amendments under 21 CFR Part 211 and ICH Q10 quality system expectations. Supply forecasting teams will need to reconcile commercial demand models against the existing PNH and aHUS supply commitments before any launch readiness declaration.

Regulatory affairs leads should also note that IgA nephropathy has seen accelerated agency interest following recent approvals in the class, raising the bar for comparator context in any submission dossier. AstraZeneca's interim data will need to be read against the full clinical dataset before a complete response package can be assembled, and the robustness of the 34-week UPCR reduction will be scrutinised alongside longer-term renal function endpoints.

The next measurable checkpoint is the trial's full dataset readout, which will determine whether the interim UPCR reduction translates into durable proteinuria control and whether AstraZeneca proceeds to formal regulatory submission across both major markets.

Source: Media4Growth via Indian Pharma Post, 8 June 2026.